A Novel Transdermal Therapeutic System as a Potential Treatment for Alzheimer’s Disease

Levy, Drora; Glikfeld, Peretz; Grunfeld, Yona; Grunwald, Jacob; Kushnir, M.; Levy, Aharon; Meshulam, Yacov; Spiegelstein, M.; Zehavi, Dov; Fisher, Abraham

doi:10.1007/978-1-4613-2179-8_63

Cited by 3 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…designed a formulation pad (3.6 cm × 3.6 cm) in 1986 which consisted of physostigmine in enhancer vehicle propionic acid and an ethylene/vinylacetate copolymer membrane with an adhesive on one side and an aluminum foil cover on its back. [ 40 41 ] The human study with this structure showed that a stable plasma concentration was recorded at 0.56 ± 0.1 ng/ml during the test and correlated well with blood acetyl-cholinesterase inhibition. [ 18 ] Consequently, physostigmine transdermal system was fabricated by Lohmann Therapie-Systeme GmbH that contained 30 mg active molecular in surface area 30.2 cm 2 .…”

Section: Transdermal For Alzheimer's Diseasementioning

confidence: 99%

Current advances in transdermal delivery of drugs for alzheimer's disease

Nguyen

Giau

Vo³

2017

Indian J Pharmacol

View full text Add to dashboard Cite

Section: Transdermal For Alzheimer's Diseasementioning

confidence: 99%

Current advances in transdermal delivery of drugs for alzheimer's disease

Nguyen

Giau

Vo³

2017

Indian J Pharmacol

View full text Add to dashboard Cite

“…One reason could be its low bioavailability in humans ( Whelpton and Hurst, 1985). Attempts have been made to improve this situation by developing a transdermal delivery system (Levy et aL, 1986) (Marta et aL, 1988b andYu et aL, 1988).…”

Section: Cholinesterase Inhibitors (Fig 5)mentioning

confidence: 99%

The Families of Cognition Enhancers

Fröstl¹,

Maitre²

1989

Pharmacopsychiatry

View full text Add to dashboard Cite

An attempt has been made to classify the numerous drugs used to treat cognition deficits according to their chemical structures and to their main physiological effects. Particular emphasis has been given to the following families: Piracetam-type, Co-dergocrine-type and vincamine-type compounds; cholinergic agents, psychostimulants, vasodilators, antianoxic agents, peptides, growth factors and gangliosides. Compounds described in the scientific literature and in patents are presented. Reference has been made to preclinical and clinical studies (973 quotations from original articles, 100 quotations of reviews and books).

show abstract

Current and Future Nano-Carrier-Based Approaches in the Treatment of Alzheimer’s Disease

et al. 2023

View full text Add to dashboard Cite

It is a very alarming situation for the globe because 55 million humans are estimated to be affected by Alzheimer’s disease (AD) worldwide, and still it is increasing at the rapid speed of 10 million cases per year worldwide. This is an urgent reminder for better research and treatment due to the unavailability of a permanent medication for neurodegenerative disorders like AD. The lack of drugs for neurodegenerative disorder treatment is due to the complexity of the structure of the brain, mainly due to blood–brain barrier, because blood–brain drug molecules must enter the brain compartment. There are several novel and conventional formulation approaches that can be employed for the transportation of drug molecules to the target site in the brain, such as oral, intravenous, gene delivery, surgically implanted intraventricular catheter, nasal and liposomal hydrogels, and repurposing old drugs. A drug’s lipophilicity influences metabolic activity in addition to membrane permeability because lipophilic substances have a higher affinity for metabolic enzymes. As a result, the higher a drug’s lipophilicity is, the higher its permeability and metabolic clearance. AD is currently incurable, and the medicines available merely cure the symptoms or slow the illness’s progression. In the next 20 years, the World Health Organization (WHO) predicts that neurodegenerative illnesses affecting motor function will become the second-leading cause of mortality. The current article provides a brief overview of recent advances in brain drug delivery for AD therapy.

show abstract

A Novel Transdermal Therapeutic System as a Potential Treatment for Alzheimer’s Disease

Cited by 3 publications

References 8 publications

Current advances in transdermal delivery of drugs for alzheimer's disease

Current advances in transdermal delivery of drugs for alzheimer's disease

The Families of Cognition Enhancers

Current and Future Nano-Carrier-Based Approaches in the Treatment of Alzheimer’s Disease

Contact Info

Product

Resources

About